Related Experiment Videos
[High throughput screening method of potassium channel regulators].
Ya-ping Pan1, Xiang-hua Xu, Xiao-liang Wang
1Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|May 7, 2004
Summary
A new fluorescence assay using DiBAC4(3) was developed for high-throughput screening of potassium channel regulators. This cost-effective and repeatable method identified nine potential regulators from 76 compounds, aiding in the discovery of novel therapeutic targets.
Area of Science:
- Pharmacology
- Neuroscience
- Biochemistry
Context:
- Potassium channels are crucial for regulating cell membrane potential.
- Discovering novel potassium channel modulators is essential for treating various diseases.
- High-throughput screening (HTS) methods are vital for accelerating drug discovery.
Purpose:
- To establish and validate a novel, cost-effective, and repeatable in vitro fluorescence assay for high-throughput screening of potassium channel regulators.
- To utilize the DiBAC4(3) fluorescence assay to screen a library of compounds for their effects on potassium channel activity.
- To identify novel compounds that modulate potassium channel function for potential therapeutic applications.
Summary:
- A cell-based 96-well fluorescence assay using DiBAC4(3) was developed in PC12 cells to measure membrane potential changes.
- The assay successfully detected responses to known potassium channel blockers and openers, with several compounds showing concentration-dependent effects.
- Out of 76 screened compounds, nine demonstrated dose-dependent fluorescence changes, indicating their potential as potassium channel regulators, requiring further validation with patch clamp techniques.
Impact:
- Provides a robust and economical HTS platform for identifying new potassium channel modulators.
- Facilitates the discovery of novel therapeutic agents targeting conditions associated with potassium channel dysfunction.
- Accelerates the drug discovery pipeline for neurological, cardiovascular, and other diseases linked to potassium channel activity.